These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6825110)

  • 1. Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.
    Lu K; Yap HY; Loo TL
    Cancer Res; 1983 Mar; 43(3):1405-8. PubMed ID: 6825110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.
    Yap HY; Blumenschein GR; Keating MJ; Hortobagyi GN; Tashima CK; Loo TL
    Cancer Treat Rep; 1980; 64(2-3):279-83. PubMed ID: 7407762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate.
    Zeffren J; Yagoda A; Kelsen D; Winn R
    Anticancer Res; 1984; 4(6):411-3. PubMed ID: 6517534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of vindesine infusion.
    Rahmani R; Kleisbauer JP; Cano JP; Martin M; Barbet J
    Cancer Treat Rep; 1985; 69(7-8):839-44. PubMed ID: 2410121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.
    Ohnuma T; Norton L; Andrejczuk A; Holland JF
    Cancer Res; 1985 Jan; 45(1):464-9. PubMed ID: 3965152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
    Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
    Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
    Kearns CM; Blakley RL; Santana VM; Crom WR
    Cancer Res; 1994 Mar; 54(5):1235-9. PubMed ID: 7906999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer.
    Yap HY; Blumenschein GR; Hortobagyi GN; Buzdar AU; Schell FC; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):511-4. PubMed ID: 7180829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
    Winer EP; Chu L; Spicer DV
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9. PubMed ID: 7740337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
    Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mitomycin C in humans.
    den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
    Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
    Burgess DS; Summers KK; Hardin TC
    Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
    Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
    Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.